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Abstract
Malaria transmission-blocking (T-B) interventions are essential for malaria elimination. Small molecules that inhibit the
Plasmodium ookinete-to-oocyst transition in the midgut of Anopheles mosquitoes, thereby blocking sporogony, represent
one approach to achieving this goal. Chondroitin sulfate glycosaminoglycans (CS-GAGs) on the Anopheles gambiae midgut
surface are putative ligands for Plasmodium falciparum ookinetes. We hypothesized that our synthetic polysulfonated
polymer, VS1, acting as a decoy molecular mimetic of midgut CS-GAGs confers malaria T-B activity. In our study, VS1
repeatedly reduced midgut oocyst development by as much as 99% (P,0.0001) in mosquitoes fed with P. falciparum and
Plasmodium berghei. Through direct-binding assays, we observed that VS1 bound to two critical ookinete micronemal
proteins, each containing at least one von Willebrand factor A (vWA) domain: (i) circumsporozoite protein and
thrombospondin-related anonymous protein-related protein (CTRP) and (ii) vWA domain-related protein (WARP). By
immunofluorescence microscopy, we observed that VS1 stains permeabilized P. falciparum and P. berghei ookinetes but
does not stain P. berghei CTRP knockouts or transgenic parasites lacking the vWA domains of CTRP while retaining the
thrombospondin repeat region. We produced structural homology models of the first vWA domain of CTRP and identified,
as expected, putative GAG-binding sites on CTRP that align closely with those predicted for the human vWA A1 domain and
the Toxoplasma gondii MIC2 adhesin. Importantly, the models also identified patches of electropositive residues that may
extend CTRP’s GAG-binding motif and thus potentiate VS1 binding. Our molecule binds to a critical, conserved ookinete
protein, CTRP, and exhibits potent malaria T-B activity. This study lays the framework for a high-throughput screen of
existing libraries of safe compounds to identify those with potent T-B activity. We envision that such compounds when used
as partner drugs with current antimalarial regimens and with RTS,S vaccine delivery could prevent the transmission of drug-
resistant and vaccine-breakthrough strains.
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Introduction
Each year more than half a million people die from malaria, a
disease caused by protozoan parasites in the genus Plasmodium. The
life cycle of Plasmodium parasites includes asexual development in
the human host and obligatory sporogonic development in the
Anopheles mosquito vector with transmission from person to person
only made possible through the bite of an infected anopheline.
Despite substantial investment in malaria research, it is widely
accepted that current interventions are insufficient to achieve the
ultimate goal of eradication and that a combination of anti-
malaria strategies including those that target parasite transmission
give eradication efforts the best chance to succeed [1]. Moreover,
the evolutionary capacity of vectors and parasites to overcome
chemical- and drug-based interventions emphasizes the need for
new weapons in the anti-malaria arsenal. It is in this context that
malaria transmission-blocking (T-B) interventions (vaccines and
drugs) have received significant attention [2]. In fact, recent
progress has shown that probing the basic biology underlying
mosquito-Plasmodium interactions can identify novel intervention
targets not only in the parasite, but in the mosquito as well [3–6].
Importantly, seminal work by Delves, et al. [7] have brought
increased attention to the potential T-B activity of drugs that failed
to demonstrate efficacy against Plasmodium asexual stages but have
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been resurrected as novel T-B candidate compounds. These efforts
highlight the need for T-B molecules and open new avenues for
the development and/or repurposing of compounds that have
direct activity against the parasite soon after ingestion into the
mosquito midgut during blood feeding.
In the mosquito blood meal, Plasmodium gametocytes differen-
tiate into gametes and fuse to form zygotes, which then develop
into motile ookinetes. For parasite development to continue,
ookinetes must find and adhere to membrane-associated ligands
on the midgut epithelial surface, a pre-requisite for cell invasion.
Experimental evidence from Plasmodium berghei and Plasmodium
falciparum suggests that ookinete attachment and invasion is
mediated by micronemal proteins, including the circumsporozoite
protein and thrombospondin-related anonymous protein-related
protein (CTRP) [8–13] and von Willebrand factor A domain-
related protein (WARP) [10,14]. The function of WARP is
unclear, while CTRP has a demonstrated role in ookinete motility
[9,15]. However, both are essential for midgut epithelial cell
invasion by Plasmodium ookinetes. Once inside the cell, ookinetes
make their way to the midgut basal lamina where they differentiate
into oocysts, each giving rise to thousands of sporozoites that are
released into the hemocoel upon maturation and rupture.
Sporozoites are then swept into the circulating hemolymph and
carried to the salivary glands. Following successful salivary gland
invasion, sporozoites remain in the lumen of the salivary duct until
host delivery during blood feeding. Clearly, negotiating the midgut
tissue barrier in the vector is crucial for successful establishment of
the parasite in the mosquito and hence, subsequent transmission to
human hosts.
In this study we exploit knowledge of crucial molecular
interactions between Plasmodium ookinetes and the apical microvillar
surface of the mosquito midgut to design proof-of-concept small
molecules that interfere with ookinete attachment. Previous work
demonstrated that sulfated glycosaminoglycans (GAGs) are present
on both the apical and basal surfaces of the midgut epithelium, with
chondroitin sulfate (CS) predominant on the apical side (i.e., facing
the midgut lumen) and heparan sulfate (HS) predominant on the
basal side [5,16] (Figure S1A). RNAi-mediated knockdown of the
Anopheles gambiae peptide-O-xylosyltransferase, an enzyme that
catalyzes the first step in CS and HS biosynthesis, resulted in
mosquitoes with CS-depleted midgut apical surfaces [5]. When
infected with P. falciparum and P. berghei in feeding assays, these
mosquitoes demonstrated significantly lower oocyst infection
intensities relative to controls. The study also showed binding
affinity for two types of CS (CS-A and CS-E) in mature ookinetes,
consistent with a previous report demonstrating that the ookinete
micronemal proteins PfWARP and PfCTRP bind to sulfated GAGs
in vitro [10]. Inspired by the idea that these molecular interactions
could be disrupted by small molecules that mimic the charged
structural elements involved in ligand binding, two short-chain,
water-soluble compounds were synthesized for in vitro and in vivo T-B
studies based on their potential to interfere with parasite protein-
GAG interactions (Figure 1A).
Here we describe efforts to test this strategy with the underlying
hypothesis that when a mosquito ingests these small molecules in
an infectious blood meal, the compounds will interfere with
ookinete-GAG interactions, therefore preventing midgut invasion
and abrogating subsequent developmental steps in sporogony.
Based on key studies in the literature [9–15], we further
hypothesize that the molecular basis of ookinete-GAG interac-
tions, and hence those between ookinetes and our GAG-mimetics,
involve the Plasmodium micronemal proteins CTRP and/or
WARP. Our findings showed that this novel strategy dramatically
reduced infection intensity in the mosquito midgut, and multiple
lines of evidence suggest that the mechanism underlying the T-B
effect involved binding of our GAG-mimetic decoy to one or more
von Willebrand factor A (vWA) domains found in the protein
CTRP.
Materials and Methods
Synthesis of small molecule inhibitors
Synthesis of polysulfonated polymers (VS1 and VS2-PVP)
proceeded with the addition of 100 mg of potassium persulfate to
5 g (0.38 mmol) of vinyl-sulfonic acid (VS1) sodium salt water
solution and adjusted to basic pH with sodium hydroxide. The
final solution was warmed for 20 hr at 80uC, then cooled to room
temperature (RT), diluted with water and ultra-filtered through a
membrane with a nominal cut-off of 10,000 Da. The fraction
retained was freeze-dried and the product obtained was a white
powder. Size exclusion chromatography was used following
different reaction times to obtain oligomers of different length
and molecular mass. These compounds were then purified by
ultra-filtration through different cut-off membranes (500 Da, 1000
Da, 5000 Da), and average molecular weights were measured by
size exclusion chromatography and MALDI spectrometry.
Parasites, mosquito maintenance and transmission-
blocking assays
Transmission-blocking assays for vinyl-sulfonic acid compounds
(including preliminary VS1 and VS2-PVP experiments) were tested
using both in vivo and in vitro systems. In vivo studies were performed
using the murine malaria parasite P. berghei (ANKA 2.34) following
IACUC approved protocols. For each experiment, two to three
naı¨ve, donor mice (Swiss Webster, 20–24 g) were inoculated (i.v.)
with blood stage P. berghei and then checked for parasitemia by blood
smear five to six days later. Once parasitemia reached $10%,
donors were sacrificed via cardiac puncture and parasitemic blood
was used to inoculate (i.v.) eight to ten experimental mice per test
compound. Two to three days post-inoculation, experimental mice
Author Summary
To achieve malaria elimination, the consensus expert
opinion is that new approaches to drug and vaccine
design are desperately needed. We have undertaken a
novel, comprehensive approach towards the development
of a malaria transmission-blocking drug based on the
strategy of inhibiting Plasmodium development in the
mosquito by interfering with obligate cellular interactions
between the parasite and the mosquito-midgut epitheli-
um. We have successfully designed a potent transmission-
blocking small molecule (VS1) that mimics the structure of
molecules on the mosquito-midgut surface called glycos-
aminoglycans (GAG), which are thought to serve as ligands
for parasite attachment prior to cell invasion. Using assays
in which mosquitoes were fed with infectious blood, we
tested the effect of VS1 on Plasmodium development in
the mosquito and found that the GAG mimic dramatically
reduced the intensity of infection in the midgut. Binding
experiments and immunofluorescence microscopy indi-
cate that VS1 binds to the circumsporozoite- and TRAP-
related protein (CTRP), a micronemal protein expressed by
ookinetes essential for midgut invasion. This interaction
profoundly inhibits a key step of parasite development,
thereby abrogating downstream events necessary for
mosquito-to-human transmission. The work described lays
the framework for bringing a truly novel transmission-
blocking drug to fruition.
Small Molecule Inhibitor of Malaria Transmission
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were smeared and checked for exflagellating gametocytes. Mice
demonstrating an average of at least 1 and fewer than 6
exflagellations per 406 field were assigned to a treatment group,
weighed and anesthetized. For each mouse, a pre-injection 500 ml
cup of Anopheles stephensi mosquitoes (n= 50) were allowed to feed for
15 to 20 min. The mouse was then removed from the mosquito cup,
injected with either a vinyl sulfonic acid compound (250 mg/ml or
500 mg per 24 g body weight), polyvinylpyrrolidone (PVP, same
dose as VS1or VS2-PVP), or the carrier only (PBS) via tail vein
injection (iv) and then allowed to recover for 10 to 15 min.
Following recovery, a post-injection cup of mosquitoes (n= 50) was
allowed to feed as before. Unfed mosquitoes were then removed
from both pre- and post-injection cups via mouth aspiration. For
each control and test compound, three to five pre- and post-
injection sets of mosquitoes were maintained on sucrose and water
for 10 days at 19uC, 80% relative humidity. On day 10, midguts
were dissected from all surviving mosquitoes and stained with 0.1%
mercurochrome for 20 mins. Oocyst number for each midgut was
determined by microscopy and at least three independent
experiments were performed for each compound.
In vitro studies were performed using the human malaria parasite
P. falciparum and the old-world malaria vectors Anopheles gambiae
and An. stephensi as described [4–5]. With the exception of the
parasite load experiment, each set of studies consisted of
independent experiments in which the age of the gametocyte
culture (16–17 days), the age of mosquitoes (4–6 days), and the
blood-meal gametocytemia (0.3%) and hematocrit (45%) were
kept consistent. In the parasite-load experiment, all else was the
same except for the blood-meal gametocytemia which varied as
described in the Results. For each experimental treatment, VS1 or
the control compound (PVP) were prepared in PBS and diluted
1:10 to the final experimental dose with infected blood.
Recombinant PvCTRP and PvWARP expression
Full-length PvWARP excluding the signal peptide (nt 88–867)
and a fragment of PvCTRP containing the first vWA domain (nt
79–921) were PCR-amplified from genomic DNA of the Salvador
I strain with a C-terminal 66His tag appended to the reverse
primer. Fragments were cloned into the EcoRV sites of the vector
pEU-E01-MCS (Cell Free Sciences, Matsuyama, Japan). The
PvCTRP-vWA1 and PvWARP were expressed in the wheat germ
cell-free expression system (Cell Free Sciences, Matsuyama, Japan)
as described [17] and purified using Ni-affinity chromatography.
ELISA-based binding and competition assays
Biotinylated VS1-NH2 in a volume of 100 ml (10 mg/ml) was
applied to each well of a streptavidin-coated (2 mg/ml) 96-well
microtiter plate that had been blocked with PBS, 1% BSA
(Thermo Pierce) and incubated for two hours at RT. During VS1
incubation, 66His-tagged recombinant PvWARP and PvCTRP
(5 mg/ml) were each mixed separately with heparin and CSA
(100 mg/ml) in blocking buffer and incubated for 2 hr at RT. The
microtiter plate was subsequently washed three times with PBS to
remove excess VS1, and then 100 ml of 66His-tagged recombi-
nant PvWARP or PvCTRP alone (10 or 5 mg/ml) or of the
recombinant protein-GAG mixture was added to each well, with
the exception of the no-protein and irrelevant-protein controls.
The latter received a 66His-tagged recombinant glycosyltransfer-
ase from An. gambiae. Binding and/or competition with VS1 was
allowed to proceed for 2 hr at RT. Following three washes with
PBS, anti-His MAb (Sigma) was added to each well and incubated
for 1 hr at RT. After three washes with PBS + Tween-20 (0.05%),
anti-mouse secondary antibodies conjugated to HRP were added
and incubated for 1 hr at RT. Following another wash step, TMB
ELISA substrate (Pierce) was used for detection. VS1 binding was
quantified by measuring the OD at 450 nm with a SPECTRA
MAX PLUS microplate reader (Molecular Devices).
Immunofluorescence microscopy assays
Ookinete samples were fixed with 4% paraformaldehyde and
prepared for immunofluorescence microscopy by washing three
times with PBS containing 0.1 M glycine (rinsing buffer). To
permeabilize samples the parasites were incubated with rinsing
buffer containing 0.2% Triton X-100 for 10 min and then washed
as before. After the washes, samples were incubated in rinsing
buffer for 30 min and blocked with PBS containing 0.05 mM
glycine, 0.2% fish skin gelatin and 0.05% sodium azide for 2 hr.
The samples were then incubated with biotinylated-VS1 and anti-
Pbs21 (P. berghei) or anti-Pfs28 (P. falciparum) for 1 hr at RT or
overnight at 4uC. Cells were washed as before and incubated with
Streptavidin, DyLight 488 conjugated (Thermo), and Goat Anti-
Rabbit IgG (H+L), DyLight 594 conjugated, for 1 hr at RT.
Following incubation, the cells were washed three times with
rinsing buffer, resuspended in PBS, spotted on slides and allowed
to air dry. ProLong Gold antifade reagent with DAPI (Invitrogen)
was added prior to the coverslip and slides were incubated for
24 hr at RT protected from light. Samples were examined with
SPOT software using a Nikon Upright E800 microscope.
Homology models
Homology modeling of the CTRP vWA domain was performed
using SWISS-MODEL in two different modes of operation [18–
21]. In the full-automated mode, the Toxoplasma gondii micronemal
protein 2 I domain (2XGG, chain B, residues 75–212) was selected
as the optimal template to calculate the CTRP model (residues 1–
148) and is based on 22% sequence identity. In the template
identification mode and using the InterPro Domain Scan method
[22], the von Willebrand factor A1 domain (1AUQ, chain A,
residues 1276–1463) was selected as the optimal target template
(residues 1–193). The model quality was assessed using the
QMEAN server [23] and the Z-score.
Statistical methods
To determine significance between treatment and control
groups in the feeding assays, the nonparametric Mann-Whitney
U test was used due to the non-normal distributions typical of
Figure 1. VS1 exhibits marked transmission-blocking activity against P. falciparum in two divergent anopheline species. (A) Structure
of compounds designed to interfere with ionic interactions between Plasmodium ookinetes and midgut apical-surface associated
glycosaminoglycans (Figure S1A). The table indicates the average molecular weight (MW) and polydispersity index (PDI) for each species of
compound tested in the study. (B–C) Results from representative replicate SMFAs showing P. falciparum midgut-oocyst intensities in An. gambiae
plotted by treatment group. Below each graph, experimental details are provided, where N is the number of mosquito midguts dissected and scored
for oocysts, prev is the infection prevalence among mosquitoes in a given treatment group, median is the median oocyst number, mean is the mean
oocyst number, and % inhibition is calculated as (mediancontrol – mediantreatment)/mediancontrol. (D–E) Same as panels B–C except that An. stephensi
were used. The level of statistical significance is denoted by asterisks following Bonferroni correction of z-scores, * = p,0.05, ** = p,0.01,
*** = p,0.001.
doi:10.1371/journal.ppat.1003757.g001
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oocyst counts. For the in vitro assays, the test was performed
comparing the distribution of oocyst counts per midgut for each
treatment group to that of the PVP control, followed by a
Bonferroni correction of z-scores to adjust for multiple tests. For
the in vivo assays, the test was performed comparing oocyst counts
per midgut between mosquitoes fed on P. berghei-infected mice pre-
and post-injection with VS1, PVP, or PBS alone.
Ethics statement
All experimental studies using vertebrate animals (mice) were
performed in accordance with Johns Hopkins University (JHU)
ACUC (Animal Welfare Assurance #A3272-1) regulations. The
Animal Protocol (#MO12H232) used for these studies was
reviewed and approved by the JHU ACUC and are in compliance
with the United States Animal Welfare Act regulations and Public
Health Service (PHS) Policy. No human subject research was
performed during this study.
Results
Small molecule inhibitors exhibit Plasmodium falciparum
transmission-blocking activity
Our primary goal was to design synthetic polymers that can
mimic sulfated CS-GAGs that have been shown to bind ookinetes
(Figure 1A, Figure S1A). However, the likelihood of CS-GAGs,
with C4S and C6S sulfation on the midgut microvillar surface was
challenged [16]. Using capillary electrophoresis with laser-induced
fluorescence detection, we confirmed the presence of both C4S
and C6S chondroitin GAGs on An. gambiae midgut brush border
microvilli vesicles (Figure S1A, Text S1). Based on these data, we
hypothesized that polymers with high sulfation densities would be
appropriate for our study. As such, two polysulfonated polymers
were generated by polymerization of vinyl-sulfonic acid (VS1) and
copolymerization of vinyl-sulfonic acid with 1-vinyl-2-pyrrolidone
(VS2-PVP). The sulfate groups on the polysulfonated polymers are
anionic at physiologic pH and would presumably bind to ookinete
proteins that would naturally bind to GAGs on the midgut surface.
Note that it was previously shown that the blocking phenomenon
is predicted to occur at the apical midgut surface, and that basal
lamina GAGs do not influence the ultimate read-out of these T-B
studies, which is oocyst prevalence and intensity measurements at
8 or 10 days post-blood feeding, for P. falciparum and P. berghei,
respectively [5].
Initial data from malaria T-B studies indicated that VS1 was
non-toxic and well tolerated by both mice and mosquitoes.
Although VS2-PVP was tolerated by mice, mosquitoes that
ingested the compound had poor survivorship in multiple
experiments within 24 hrs following blood feeding. This low
survivorship prevented a proper comparison of infection intensity
between midguts dissected from pre- and post-injection mosqui-
toes; and consequently, this compound was not pursued further. In
preliminary in vitro standard membrane feeding assays (SMFAs),
VS1 demonstrated 98.5% and 92.3% inhibition of P. falciparum
oocyst development in An. gambiae and An. stephensi, respectively. In
vivo direct feeding assays (DFA) with mice infected with P. berghei
demonstrated a somewhat lower effect of the compounds on
parasite development in An. stephensi, with VS1 reducing oocyst
intensity relative to controls by 77%. These preliminary data from
both in vitro and in vivo malaria models demonstrated the potential
for VS1 to act as a potent T-B compound. Moreover, to exclude
the possibility that micro- and macrogamete fertilization events
could be adversely affected by VS1, we tested the effect of the
compound on male microgamete exflagellation and noted that the
number of exflagellation centers were unaffected (data not shown).
We therefore pushed this small molecule forward as the lead
compound for further testing, which included (i) assays to
determine if T-B activity varies according to polymer length, (ii)
dose-ranging assays to estimate the IC50 of VS1, (iii) ELISA-based
binding and competition assays using a candidate gene approach,
specifically recombinant versions of the ookinete micronemal
proteins CTRP and WARP, and (iv) immunofluorescence
Table 1. Summary of the results from two replicate direct feeding assays (DFA) for each VS1 compound using Anopheles stephensi
that fed on Plasmodium berghei ANKA 2.34 -infected mice pre- and post-injection with either PBS (carrier-only control), PVP (non-





















10,000 (1) 48.1 80.1 235.2 NS 82.5 47.9 33.7 NS 90.0 3.3 91.1 ,0.0001
(25.34) (59.68) (50.81) (23.95) (10.28) (9.58) (37.33) (1.65) (5.55)
10,000 (2) 46.0 24.8 47.3 0.0008 16.3 16.4 251.4 NS 2.0 0.5 53.3 ,0.0001
(16.84) (11.24) (13.12) (6.20) (7.04) (80.41) (0.37) (0.26) (15.92)
3,000 (1) 53.5 30.8 40.4 0.0012 17.9 12.4 212.6 NS 27.0 0.3 98.8 ,0.0001
(22.83) (13.23) (3.81) (10.68) (5.68) (61.55) (4.86) (0.22) (1.12)
3,000 (2) 55.8 60.5 264.2 NS 53.4 28.9 48.2 0.0001 54.8 1.3 98.0 ,0.0001
(24.10) (17.72) (43.61) (13.06) (11.78) (9.96) (14.79) (0.56) (0.80)
1,000 (1) 16.8 12.5 23.2 NS 16.5 13.3 22.6 NS 14.6 1.0 92.1 ,0.0001
(10.30) (5.75) (16.66) (5.95) (4.87) (29.05) (2.93) (0.00) (1.76)
1,000 (2) 41.1 107.5 2140.2 NS 68.6 63.5 27.6 NS 94.6 2.0 97.8 ,0.0001
(4.80) (16.91) (131.38) (40.57) (37.77) (46.54) (13.27) (0.73) (0.92)
For each treatment group, the data are summarized into four columns. In the first two columns, the means of the median number of oocysts per mosquito for 4–5 mice
per group are given for pre- and post-injection feedings, respectively, with the standard error for each reported in parentheses below the mean. In the third column, the
means of percent Inhibition, calculated as the average of (medianpre – medianpost)/medianpre for each mouse, are reported for each treatment group along with
standard errors in parentheses. In the fourth column, P-value results of Mann-Whitney U tests are reported for each set of pre- and post-injection feedings. Only P-values
that are significant at a Bonferroni-corrected alpha of 0.0028 are given. NS, non-significant.
doi:10.1371/journal.ppat.1003757.t001
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microscopy to confirm binding of VS1 to wild-type ookinetes from
both P. falciparum and P. berghei, as well as ookinetes from knockout
lines of P. berghei.
VS1 demonstrates potent transmission-blocking activity
across ranges of polymer length, parasite load, and
polymer concentration
To assess the influence of polymer length, the product following
VS1 synthesis was fractionated into three molecular-weight
categories by size exclusion chromatography, VS1-10,000; VS1-
3,000; and VS1-1,000 (Figure 1A). Based on preliminary dose
ranging experiments, each new compound was then tested at a
concentration of 250 mg/ml using both in vitro (SMFA) and in vivo
(DFA) malaria models. Polyvinylpyrrolidone, a non-sulfated,
neutrally charged control (PVP), which represents the unsulfated
VS1 backbone, was used as a control. In SMFAs the three VS1
compounds were tested in parallel against P. falciparum in two
replicate experiments using two different vector species, An. gambiae
and An. stephensi. In all four experiments, each of the VS1
compounds significantly reduced oocyst intensity (Figure 1B–E).
VS1-3,000 consistently performed the best; inhibiting oocyst
development by 86.0%–99.0% in An. gambiae (Figure 1 B, C)
and 88.0%–93.5% in An. stephensi (Figure 1 D, E). Experiments
with the in vivo system yielded similar results, as all three VS1
compounds strongly inhibited P. berghei oocyst development in An.
stephensi (Table 1, Figure 2, Table S1). Results from two replicate
experiments per compound showed that all six VS1 treatment
groups experienced a highly significant reduction in median oocyst
intensity when comparing mosquitoes fed on pre-injection mice
with those fed on mice injected with VS1 (Table 1, Table S1). In
five of these treatment groups, oocyst development was inhibited
by .90%. VS1-3,000 had the strongest effect, demonstrating
$98.0% inhibition on average in both experiments (Table 1,
Table S1B). Conversely, pre- and post-injection comparisons of
the oocyst burden in mosquitoes fed on mice from PBS and PVP
groups demonstrated no consistent effect of either the VS1 carrier
or the unsulfated polymer (Table 1, Table S1). To confirm that
VS1 was available to mosquitoes in blood meals, and hence the
likely cause of T-B activity, the presence of VS1 in the mouse
bloodstream following injection was confirmed by HPLC (Figure
S2, Text S1).
Figure 2. VS1 exhibits malaria transmission-blocking activity in an in vivo system. Panels (A–C) show midgut oocyst intensities from a
representative experiment in which An. stephensi mosquitoes were fed on mice infected with Plasmodium berghei pre- and post-injection with VS1-
3,000. Each panel represents a different treatment group (A, PBS; B, PVP; C, VS1-3,000) and the X-axis of each is arranged by parasitized mouse
(labeled 1–5) pre- and post-injection with VS1.
doi:10.1371/journal.ppat.1003757.g002
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Due to its consistent T-B activity, VS1-3,000 was selected for
use in P. falciparum NF54 SMFA experiments to assess the
compound’s effectiveness across variations in parasite load in the
blood meal (gametocytemia) and to estimate the IC50 of VS1 in
two different anopheline vectors. For the parasite-load experi-
ments, we chose to test VS1 potency at levels of gametocytemia
that captured values routinely observed during the conduct of
membrane feeding assays in the field [24–25]. With the
concentration of VS1-3,000 set at 250 mg/ml, a SMFA was
performed in which four gametocyte concentrations were tested in
the presence and absence of VS1. In this experiment, a day 17
gametocyte culture at 3.0% gametocytemia was pelleted and the
packed red blood cells (RBCs) were diluted with uninfected blood
to 0.3% and 0.1% gametocytemia. Each of these dilutions was in
turn diluted 1:10 with uninfected blood yielding 4 concentrations
that ranged from 0.01%–0.3% gametocytemia (,800–24,000
stage V gametocytes per ml of blood). The level of gametocytemia
commonly used in laboratory-based SMFAs (0.3%) is typically
much higher than that found in the field to ensure consistent and
robust infections in mosquitoes, allowing more rigorous tests of T-
B activity [25]. Though a widely accepted approach, a criticism of
the SMFA is that the assay better tests the effects of compounds (or
antibodies) on oocyst intensity than prevalence of infection among
mosquitoes. Since the ultimate goal is to reduce the latter to zero,
we wanted to perform the SMFA over a range of gametocytemias
once we established that VS1 consistently reduces the oocyst
burden at the usual gametocytemia of 0.3%. In this set of
experiments, VS1-3,000 once again demonstrated a potent
reduction in oocyst intensity at 0.3% gametocytemia, reducing
the median oocyst number per midgut from 92.0 to 8.0
(Figure 3A). However, the prevalence of infection was unchanged
between carrier-only and VS1 treatments at this level of
gametocytemia. Interestingly, as the gametocytemia was reduced
from 0.3%, the effect of VS1 on infection prevalence increased
while the reduction in oocyst intensity remained high (Figure 3A,
B). In fact, at the two levels of gametocytemia most relevant to the
field (i.e., 0.03% and 0.01%), the median oocyst number was
reduced to 0 in the VS1 treatments while prevalence was reduced
from 89% and 67% in carrier-only treatments to 21% and 13% in
VS1 treatments, respectively (Figure 3B, C). In other words, at
levels of gametocytemia where untreated mosquitoes averaged
fewer than 5 oocysts per midgut and where most mosquitoes were
infected, VS1 treatment reduced infection prevalence 4–5 fold and
infection intensity by 10 fold. Under these conditions, most VS1-
treated mosquitoes were uninfected, while the few that were
tended to have a single oocyst.
In a set of two dose-ranging experiments with An. gambiae and
two with An. stephensi, VS1-3,000 was fed to mosquitoes in
infectious blood meals using serially diluted concentrations from
400 mg/ml to 12.5 mg/ml. The four experiments revealed a
consistent pattern of percent inhibition characterized by a linear
increase from little to no inhibition at 12.5 mg/ml to approxi-
mately 80% at 100 mg/ml and then a plateau .90% at
concentrations .200 mg/ml (Figure 3D). From these data the
IC50 of VS1-3,000 was approximated to be 25 mg/ml.
VS1 shows binding affinity to Plasmodium ookinetes
Since VS1 is a hypothesized structural mimetic of midgut-
microvillar sulfated GAGs, we sought to determine whether VS1
can directly bind to Plasmodium ookinetes. To this end, we used
biotinylated VS1-NH2 (Figure 1A) to probe non-permeabilized
and permeabilized P. berghei ookinetes generated in vitro, as well as
ex vivo blood-meal derived P. falciparum ookinetes isolated from
dissected mosquito midguts. Only permeabilized Plasmodium
ookinetes showed strong binding affinity to VS1 by immunoflu-
orescence microscopy. The VS1 staining pattern suggested that it
is not associated entirely with the ookinete surface since it did not
consistently bind to non-permeabilized ookinetes nor did it localize
with the abundant ookinete surface marker P28 (also called Pbs21
in P. berghei) in either P. falciparum (WTPf) or P. berghei (WTPb)
(Figure 4A, 4B). VS1 binding appears to be centrally and apically
localized in the cytoplasm, suggestive of interaction with micro-
nemal proteins since these proteins are not constitutively secreted
to the ookinete surface and are stored in the micronemes [10,26].
In addition to ookinetes, VS1 also bound to P. falciparum retorts
(i.e., developing ookinetes) (data not shown), and a portion of
permeabilized P. falciparum and P. berghei round cells. These cells
are likely to be zygotes or unfertilized macrogametes (Figure S3E–
L) since they are stained with P28, a surface marker well described
in the literature, which is expressed from macrogametes to early
oocyst [27–29] ruling out the possibility that these cells are P.
berghei or P. falciparum gametocytes. Furthermore, P. falciparum stage
IV and V gametocytes are not round but have a distinctive
elongated morphology, and these cells did not stain withVS1 in
subsequent immunofluorescence experiments targeting gameto-
cytes (Figure S4A–D, Text S1). We cannot rule out an effect of
VS1 in macrogametes and/or zygotes because those stages were
not the focus of the current research, but any effect in these stages
will potentiate the effect of VS1 against transmission of Plasmodium.
We evaluated the effect of VS1 in the ability of microgametes to
exflagellate in P. berghei and found that VS1 had no inhibitory
effect on exflagellation between pre- and post-injection mice
(Table S2). Furthermore, dissection of mosquitoes 24 hours after
feeding with either PBS or VS1 showed presence of ookinetes in
the blood meal (data not shown). Nevertheless, more studies are
needed to more thoroughly assess the effect of VS1 on
macrogametogenesis, fertilization, and ookinete development.
Because we are working with a T-B compound, targeting more
than one stage of the parasite in the mosquito gut would
strengthen the outcome of our final goal, completely blocking
transmission of malaria.
VS1 binds to recombinant CTRP and WARP proteins
We used a candidate gene approach to identify potential targets
or binding ligand(s) of VS1 among the repertoire of Plasmodium
ookinete micronemal proteins [30], focusing particularly on those
with established roles in midgut attachment or invasion. The
literature indicates that two such proteins, CTRP and WARP,
bind to sulfated GAGs [10]; and although both are in the
apicomplexan TRAP/MIC2 family of proteins, their domain
architectures are quite different [30]. WARP is an approximately
40 KDa protein with a signal peptide and a single vWA domain,
and we hypothesize that based on the published data WARP is
secreted from the ookinete microneme and can thus work as an
extracellular adaptor protein, potentially bridging the parasite
surface (or surface molecules) with midgut apical membrane
ligands. The much larger CTRP is approximately 230 KDa and
contains a signal peptide followed by six contiguous vWA
domains, seven contiguous thrombospondin (TS) domains, a
transmembrane domain, and a short acidic cytoplasmic domain at
the C-terminus that interacts with the motility actomyosin
machinery [30]. The first four vWA domains of CTRP are more
similar to one another than to vWA domains 5 and 6 when
comparing six species of Plasmodium. Interestingly, a phylogenetic
analysis of the vWA domains from TRAP, CTRP, and WARP
among these species shows that WARP and CTRP form a single
clade and that the vWA domain of WARP most recently shared a
common ancestor with the fifth vWA domain of CTRP, suggesting
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that WARP evolved from CTRP [30]. We emphasize that the
domain architectures and amino acid sequences of these two
proteins are highly conserved across Plasmodia [10,30] and argue
that VS1’s potency against both rodent and human malaria, as
well as its ookinete staining pattern as reported here, suggests that
VS1’s binding partner(s) is likewise highly conserved across
Plasmodia. Thus given the above and the aim of identifying the
mechanism of action for VS1, we sought to investigate the binding
activity of Plasmodium vivax CTRP and WARP to VS1, following
the argument that VS1 should bind to these two molecules. We
produced soluble recombinant WARP and the first vWA domain
of CTRP from P. vivax using a cell-free wheat germ system (Figure
S5) and evaluated binding affinity via ELISA. As expected, both
recombinant PvCTRP and PvWARP bound to VS1 in a dose-
dependent manner (Figure 4C). To better delineate binding
specificity, competition assays with heparin and chondroitin sulfate
A (CSA) were performed. If VS1 binds primarily to the putative
GAG-binding sites on the vWA domains of CTRP and WARP,
then we would expect that heparin, and perhaps to a lesser extent
CSA, at a concentration of 100 mg/ml should completely inhibit
Figure 3. Dose-ranging experiments demonstrate consistent dose-response relationships between gametocytemia, VS1, and
percent inhibition of Plasmodium infection. (A) Results from a gametocyte-dilution SMFA showing the relationship between percent
gametocytemia and midgut infection with (X% + VS1) and without (X% + PBS) VS1-3,000. The dashed box denotes the data highlighted in panel C.
(B) Results from a representative dose-ranging SMFA with An. gambiae (replicate 2 in panel D) where mosquitoes were fed P. falciparum gametocytes
in combination with VS1-3,000 in concentrations ranging from 12.5–400 mg/ml in 2-fold increments. The column headings in the table below are as in
Figure 1. (C) Results of SMFA experimental treatments in panel A from 0.1% gametocytemia and lower. The data are displayed at a scale that better
shows the range of oocyst intensities at lower gametocyte concentrations. (D) Relationship between percent inhibition and VS1 concentration from
four independent experiments. Each data point represents the percent inhibition of P. falciparum infection for a specific concentration of VS1-3,000.
Results are shown for two experiments using An. gambiae and two using An. stephensi. The dashed line approximates the IC50.
doi:10.1371/journal.ppat.1003757.g003
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Figure 4. VS1 binds to critical Plasmodium micronemal proteins. Immunofluorescence microscopy images of VS1 staining patterns of
permeabilized wild type ookinetes from (A) P. falciparum (WTPf) and (B) P. berghei (WTPb). Each row of images depicts brightfield, followed by staining
with VS1 (green), P28 (red), and the merged image of VS1, P28, and DAPI nuclear staining (blue). Note that different antibodies were used for each
Plasmodium species to stain orthologous surface markers, a-P28 for P. falciparum and a-Pbs21 for P. berghei. Size bar = 10 mm. (C) Binding assays with
recombinant P. vivax CTRP and WARP (Figure S5) demonstrate that biotinylated VS1 is recognized by PvWARP and the first vWA domain of PvCTRP.
Two representative experiments are shown with assays performed in triplicate. Black bars represent PvWARP (PvW) and gray bars represent PvCTRP
(PvC). Each protein, at two concentrations (10 and 5 mg/ml), was allowed to bind with biotinylated VS1 immobilized to a microplate, followed by
detection using an anti-HIS MAb (Sigma). In addition, competitive binding assays were performed by incubating the recombinant proteins with
heparin (HEP) and chondroitin sulfate A (CS-A) prior to incubation with VS1 and detection of PvWARP and PvCTRP binding to the VS1-coated plate as
above. A no-protein control was included in each ELISA assay and used as the background subtraction value. Error bars represent +/21 standard
deviation. (D–F) Immunofluorescence microscopy images demonstrating selective VS1 binding to ookinetes that were generated in vitro from P.
berghei (D) CTRPKO, (E) DTS7, and (F) DA6 transgenic lines. VS1 staining of DTS7 but not CTRPKO or DA6 ookinetes suggest that the vWA domain of
CTRP is the primary binding ligand of VS1, and that staining is specific to the localized expression of CTRP in micronemes. Each row of images depicts
brightfield, followed by staining with VS1 (green), P28 (red), and the merged image of VS1, P28, and DAPI nuclear staining (blue). Size bar = 10 mm.
doi:10.1371/journal.ppat.1003757.g004
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binding. However, we observed that both heparin and CSA only
partially inhibited VS1 binding to PvCTRP and PvWARP
(Figure 4C), suggesting that VS1 binds to additional sites not
used by heparin on either recombinant protein or that it binds to
them with greater affinity.
VS1 does not bind to CTRP- or vWA domain knockout
lines of P. berghei
The ELISA results demonstrated that VS1 binds to recombi-
nant WARP and the first vWA domain of CTRP in vitro, so to test
binding in vivo we obtained three lines of P. berghei in which CTRP
had been either completely [9,15] or partially knocked out [15]
and compared VS1 staining patterns by immunofluorescence
microscopy. One of the partial knockouts, a line known as DA6,
expresses CTRP that is missing all six of the vWA domains but
contains all seven of the thrombospondin domains. Conversely,
CTRP expressed by the other partial knockout line, DTS7,
includes the six vWA domains but lacks any of the thrombos-
pondin domains. Since the recombinant CTRP protein used in the
ELISA consisted only of the first vWA domain, we predicted a
priori that the VS1 binding pattern to DTS7 ookinetes would be
similar to wild type ookinetes, while the VS1 signal in both the
CTRP knockout (CTRPKO) and DA6 lines would be diminished.
However, if VS1 also binds to any of the TS domains in vivo, the
VS1 signal would be much lower in the CTRPKO than in either of
the partial knockouts. A caveat to this approach is that if VS1 also
binds to WARP in vivo, we would expect some portion of the VS1
signal observed in wild type ookinetes to be shared among all of
the knockout lines.
Immunofluorescence microscopy images from CTRPKO
(Figure 4D) indicate that VS1 binds to CTRP in permeabilized
ookinetes. Furthermore, comparisons of staining patterns from the
partial knockouts strongly suggest that VS1 binding involves vWA
domains but not the TS domains (Figure 4E, F). Furthermore, the
apparent loss of VS1 signal in both the CTRPKO and DA6 lines
also suggests that VS1 localizes to the micronemes (as suggested by
Figure 4B) and that CTRP is the primary micronemal target of
VS1and not WARP (Figure 4D, F). These data further reconcile
the observed cytoplasmic staining of putative zygotes/macroga-
metes (Figure S3) with the previously reported staining of round
forms with CTRP antisera [11]. Without a WARP knockout line
we cannot rule out that binding to WARP may occur in vivo or that
some of the T-B activity we observed is due to such an interaction.
It should be noted that WARP expression/secretion is not well
understood and may be temporally regulated or even midgut
contact-dependent for different Plasmodium species. Thus, in vitro
generated P. berghei ookinetes or P. falciparum ookinetes isolated
from the blood-meal bolus may not express detectable levels of
WARP. However, the CTRPKO and DA6 microscopy data are
persuasive and we note that VS1 binding by ELISA is consistently
stronger for the first vWA domain of CTRP than for WARP.
Moreover, the phylogenetic relationship among CTRP and
WARP vWA domains [30] in combination with the ELISA and
immunofluorescence microscopy data reported here, suggest that
VS1 primarily targets the first four vWA domains of CTRP. The
divergence of vWA domains 5 and 6 and their evolutionary
relationships with WARP suggest that these domains bind VS1
secondarily or not at all.
Homology model predicts GAG-binding sites in CTRP
vWA domain
In the absence of a CTRP crystal structure, we used homology
modeling to predict heparin-binding sites on CTRP (Figure 5A–E).
The quality of the models was assessed with QMEAN; and models 1
(PDB: 1AUQ, Figure 5B, C) and 2 (PDB: 2XGG, Figure 5 D, E)
had Qmean scores of 0.572 (Z-score =22.892) and 0.584 (Z-
score =22.314), respectively, indicating comparable model reli-
ability. Model 1 is based on the human von Willebrand factor A1
domain, while Model 2 is based on the vWA-integrin like domain
from the Toxoplasma gondii MIC2 protein. The structure of the
former has been extensively studied due to its essential role in
platelet adhesion [31–33], while the latter is a well-described
adhesin involved in host-cell invasion [34]. Despite the selection of
markedly different templates, both with low sequence identity to
CTRP (,25%), both models had the same overall a/b Rossmann
fold. The positively charged residues adopted similar patterns
between the two models (Figure 5 B–E), which were also in general
agreement with the predicted heparin-binding domains on vWFA1
(Figure 5A). A superposition of Model 1 with vWFA1 (1AUQ)
(Figure S6A–B) suggests that the two models predominantly differed
in their overall length and the conformation of the loops connecting
the beta sheet core and flanking alpha helices. A superposition of
Models 1 and 2 also demonstrated a difference in overall length as
well as the presence of a large alpha helix in Model 1 that is absent
in Model 2 (Figure S6C–D). Furthermore, a number of basic
residues fall well outside the predicted vWFA1 heparin-binding
regions in CTRP (Figures 5A–E), which may represent an extended
electropositive surface and additional binding sites for sulfated
polymers such as heparin and VS1.
Discussion
Host-cell GAGs have been shown to be important mediators of
Plasmodium development in its two hosts, including merozoite
invasion of RBCs [35–36], infected RBC sequestration to
placenta [37], ookinete invasion of the midgut [5], and sporozoite
invasion of mosquito salivary glands [38] and vertebrate
hepatocytes [39]. Here we tested a strategy that exploits this
feature of Plasmodium biology and demonstrated that VS1, a
putative GAG-mimetic, reduced midgut oocyst development by
as much as 99% in mosquitoes fed with P. falciparum or Plasmodium
berghei. Through direct-binding assays, we observed that VS1
bound to two ookinete micronemal proteins necessary for midgut
invasion, each containing at least one vWA domain: (i) CTRP
and (ii) WARP. By immunofluorescence microscopy, we observed
that VS1 stains permeabilized P. falciparum and P. berghei ookinetes
but does not stain P. berghei CTRP knockouts or transgenic
parasites lacking the vWA domains of CTRP while retaining the
thrombospondin repeat region. Finally, we used structural
homology models of the first vWA domain of CTRP to identify
residues likely involved in binding GAGs, as well as the VS1
compound. Based on these data, our working model for the
mechanism underlying VS1’s T-B activity is that it binds to
CTRP once the protein is secreted from the micronemes of
ookinetes prior to midgut attachment and invasion. CTRP is
essential for gliding motility [9,15] and contains six vWA
domains, which commonly play roles in cell adhesion to GAGs
[8,10,30–34]. Our data suggest that VS1 either interrupts the
gliding process on the midgut apical microvillar surface or coats
the surface of the ookinete through its interaction with CTRP,
thus preventing attachment to ligands (e.g., chondroitin sulfate
[5]) on the apical surface of the midgut epithelium. Nevertheless,
due to observed binding of VS1 to permeabilized round cells, we
cannot rule out that VS1 may potentially have an added benefit
and affect additional parasite stages found in the blood meal,
particularly macrogametes and/or zygotes. Further studies into
these beneficial side effects are necessary.
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When designing the GAG-mimetic strategy, data from the
literature suggested that sulfation density per disaccharide unit and
the manner of presentation (i.e., how the underlying structure of
the sugar scaffold influences the 3D projection of sulfated moieties)
are critical factors in inhibiting pathogen-GAG interactions. Boyle
et al. [35], for example, found that heparin and the E. coli-derived
K5 polysaccharide inhibits merozoite entry into RBCs and that
variations in the average number of sulfate groups/saccharide unit
Figure 5. A Homology model of Plasmodium falciparum CTRP provides insight into the potential VS1 binding motifs. (A) Amino acid
alignment of CTRP vWA domain 1 from P. falciparum (PfCTRP 1), P. berghei (PbCTRP 1), and P. vivax (PvCTRP 1) with vWA domains from P. falciparum
thrombospondin-related anonymous protein (PfTRAP), T. gondii micronemal protein 2 (TgMIC2), and human von Willebrand Factor (Hs vWF A1).
Arginine and Lysine residues are highlighted in red and motifs involved in heparin-binding in Hs vWF A1 are boxed. Secondary structural elements for
Hs vWFA1 are provided above each row of amino acids as described [32]. Arrows represent beta strands (labeled A–F), closed rectangles represent
alpha helices (labeled 1–7; a2 intentionally missing due to lack of equivalent helix relative to other human vWA domains), and open rectangles
represent 3–10 helices. (B–C) Homology model (light gray) of P. falciparum CTRP (Model 1) based on the crystal structure of the human vWF A1
domain (PDB: 1AUQ) and the same Model rotated 180u. In (B) the homology model is presented as a ribbon diagram, while a space-filling model is
shown in (C). (D–E) Homology model (steel gray) of P. falciparum CTRP based on the Toxoplasma MIC2 structure (PDB: 2XGG) and the same model
rotated 180u. In (D) the homology model is presented as a ribbon diagram, while a space-filling model is shown in (E). In (B–E) yellow residues indicate
the predicted heparin-binding domains for Models 1 and 2 that have been described for the vWF A1 domain and indicated as boxed areas in the
sequence alignment in panel (A). Red residues indicate the positively charged Arg and Lys moieties present outside of the predicted heparin-binding
domains (in yellow) for Models 1 and 2. Blue residues correspond to the putative MIDAS metal-ion binding motif [DXSXR in vWF A1, DXSXS in the
apicomplexan vWA domains included in panel (A)].
doi:10.1371/journal.ppat.1003757.g005
Small Molecule Inhibitor of Malaria Transmission
PLOS Pathogens | www.plospathogens.org 11 November 2013 | Volume 9 | Issue 11 | e1003757
for K5, which consists of glucoronate as opposed to iduronate,
exhibited different inhibitory effects against merozoites, with
sulfate densities .3/disaccharide producing the most potent
IC50 estimates. Therefore, we sought to determine the minimal
T-B polymer length of VS1 with the hope of minimizing the
likelihood of diverse structural conformations that can occur with
longer polymers, which could in turn affect the presentation/
projection of anionic moieties. Although we were able to
demonstrate that VS1-3,000 was the most effective polymer, we
cannot, however, predict its structure. VS1-3,000 is unlikely to
remain linear in solution or in the midgut after blood feeding.
With this caveat in mind, we suspect that binding to the
recombinant or native CTRP and WARP molecules may
engender a specific VS1 conformation. Regardless, we expect
that VS1 binding is largely due to the predicted GAG-binding
motifs on the vWA domain(s) of CTRP and WARP [10].
However, the concentration of heparin used in our studies, which
would otherwise result in the near complete inhibition of high
affinity protein-GAG interactions [40–42] only reduced VS1
binding by ,25%. It should be noted, however, that cases exist in
the literature where soluble heparin cannot completely outcom-
pete vWA domain-GAG interactions. For example, heparin-BSA
binding to the vWA domain of PfTRAP can be competed between
45–66% using 50 mg/ml of soluble heparin and that a 10-fold
increase in heparin concentration reduced binding to 9–27% of
control [43]. Even more striking is a report that neither a 50-, 100-
, or 1,000-fold molar excess of soluble heparin could completely
inhibit binding between the PfTRAP vWA domain and the surface
of HepG2 cells, which was thought to be GAG mediated [44]. In
this set of experiments, each concentration reduced binding by
approximately 15%, 55%, and 70%, respectively, suggesting that
the PfTRAP vWA domain utilizes both GAG and a non-GAG
binding sites. In combination, these data suggest that each
recombinant protein in our study has either stronger binding
affinity for VS1 than for either heparin or CSA, that the predicted
GAG-binding regions do not completely explain the interactions
of VS1 with PvCTRP or PvWARP, or more likely, a combination
of these two scenarios. Tertiary structures of mammalian heparin-
binding proteins have also been shown to enhance affinity and
specificity [41]. We cannot rule out the possibility of cryptic GAG-
binding sites on CTRP and WARP that provide cooperative
binding to VS1, as suggested at least in part by potential basic
residue patches identified on two homology models of the first
vWA domain of CTRP, which appears to be a primary ligand of
VS1. In terms of sulfation density and propensity to form various
non-linear conformations, VS1 is clearly different from Heparin
and natural GAGs. In this context, cooperative binding may be
conferred by VS1 ‘‘wrapping around’’ CTRP and interacting with
basic residues along different faces of the protein. The presence of
potential additional binding sites suggests that CTRP (as opposed
to other GAG binding proteins) can be specifically targeted by the
next generation of VS1-based chemical mimetics. Clearly, a
crystal structure for CTRP is needed to clarify the hypotheses
generated by our two models.
To date, the antimalarial pipeline is filled with compounds that
act on related biochemical pathways (e.g., folate biosynthesis),
which also increase the likelihood of the development of parasite
cross-resistance to these ‘‘new’’ compounds. The need to discover
drugs that act on unpredicted or uncharacterized biochemical
pathways that are completely different from those associated with
current antimalarials is paramount [45]. Our approach fits this
mold, as it represents a completely novel mechanism of action
compared to those associated with the existing, new, and now
‘‘rediscovered’’ list of antimalarials and T-B compounds [7].
Among the various T-B strategies, drugs offer a distinct
advantage over vaccines since the efficacy of the compound is
dose dependent and human immune-system independent, the
latter being a potentially significant issue given that individuals in
malaria endemic regions may suffer from malnourishment and
concomitant infections by immune-modulating pathogens such as
HIV and helminths. Although we have shown that VS1 is a potent
T-B molecule, we emphasize that it cannot be used as a drug in its
current form. However, we intend to use the data reported here to
establish a high-throughput approach for identifying a next-
generation ‘‘druggable’’ malaria T-B compound that would inhibit
ookinete invasion of the midgut beyond that observed for VS1 (i.e.,
achieve zero infection prevalence among treated mosquitoes). We
recognize, however, that if the next generation compound only
replicates the T-B activity reported for VS1 and were used alone in
the field, it would unlikely reduce infection prevalence in the
mosquito population below the threshold necessary for sustained
transmission . Nevertheless, it is widely believed that no anti-
malarial intervention on its own will lead to regional elimination
and eventual eradication [1,2]. We envision that in this context,
such compounds may be valuable in a range of epidemiologic
settings. Potential applications include (i) general use in conjunc-
tion with existing artemisinin combination therapies, which we
emphasize do not kill stage V gametocytes, to prevent recurrent
transmission from the treatment-seeking segment of the popula-
tion, (ii) use in regions with unstable malaria (e.g., highlands) to
curb transmission during epidemics, (iii) use in combination with a
T-B vaccine targeting sexual stage parasites to act as a safety net to
‘‘mop up’’ break-through parasites, and (iv) at the end game of the
malaria eradication effort, as mass distribution of T-B compounds
may offer a cost-effective approach to preventing asymptomatic,
gametocytemic individuals, who would not otherwise seek
treatment, from infecting anopheline mosquitoes, thus preventing
resurrection of epidemic malaria transmission.
Supporting Information
Figure S1 Capillary electrophoresis laser-induced fluo-
rescence (CELIF) spectroscopy identifies the C6S moiety
on chondroitin sulfate glycosaminoglycans on the apical
midgut brush border microvilli vesicles (BBMV) of
Anopheles gambiae. (A) Structure of chondroitin sulfate (CS)
disaccharide units likely found on the apical surface of midgut
epithelial cells in An. gambiae and that have been shown to bind
directly to P. falciparum ookinetes in vitro [5]. C6S is present in both
CSC and CSE. (B) CELIF analysis. Trace A, baseline An. gambiae
midgut BBMV isolated from 1,500 5–6 day old female, sugar fed An.
gambiae. Trace B, BBMV + DDi6S disaccharide added to the
sample. Trace C, BBMV + DDi4S and DDi6S disaccharides added.
Trace D, Chondroitin sulfate C (CSC) control. Red arrows indicate
the presence of C4S and C6S modifications to chondroitin sulfate
on the midgut surface, as evident from the increased peak intensities
following the addition of the disaccharides as compared to the CSC
control which has both C4S and C6S modifications.
(TIF)
Figure S2 HPLC-based quantification of VS1 in mouse
blood. (A) Peak absorbance at 210 nm was measured for VS1-
biotin standards ranging in concentration of biotin from 25–
200 nmol/ml (corresponds to 0.1375–1.1 mg/ml of biotinylated
VS1-NH2). The table below the graph provides the integrated area
under the peak for each standard, as well as those values with the
blank subtracted (Areasub). The inset graph shows the standard
curve generated from the linear relationship of integrated area
under the peak and concentration of biotin. (B) Peak absorbance
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at 210 nm was measured for three technical replicates (TR) of
VS1-biotin isolated from mouse blood. The table below the graph
reports integrated area under the peak for each TR, those values
with the blank subtracted (Areasub), and the estimated concentra-
tion based on the standard curve.
(TIF)
Figure S3 Additional microscopy images demonstrating
VS1 binding to mosquito-stage parasites. (A–D) Brightfield
and immunofluorescence microscopy images of VS1 staining
patterns of permeabilized wild type ookinetes from P. berghei. Each
pair of images depicts brightfield (A, C), followed by staining with
VS1 (green) merged with DAPI nuclear staining (blue) (B, D). The
arrow in panel B highlights greater VS1 staining intensity apically.
Size bar = 10 mm. (E–L) Microscopy images of VS1 staining
patterns of permeabilized round cells from wild type P. falciparum
(E–H) and P. berghei (I–L). Each row of images depicts brightfield
(E,I), followed by staining with Pfs25 (red) (F) or P28 (red) (J), VS1
(green) (G, K), and the merged image of VS1, PfS25/P28, and
DAPI nuclear staining (blue). Size bar = 10 mm.
(TIF)
Figure S4 Plasmodium gametocytes are not stained
with biotinylated VS1. (A–D) Brightfield and fluorescence
microscopy images of VS1 staining patterns for non-permeabilized
wild type gametocytes from P. berghei (A–B) and P. falciparum (C–D).
Each pair of images depicts brightfield (A, C), followed by staining
with VS1 (red) merged with DAPI nuclear staining (blue) (B, D).
Black and white arrows denote the location of the gametocytes.
Size bar = 10 mm.
(TIF)
Figure S5 SDS-PAGE gel demonstrating the wheat germ
cell free system for soluble expression of His-tagged
recombinant Plasmodium vivaxCTRP andWARP.Asterisks
denote the sample material used in subsequent assays. M: molecular
weight marker. T: Total translation mix. S: Supernatant. P: Pellet. Ft:
Flow through. Ne: Non-reducing condition elution. Re: Reducing
condition elution. R: Resin. Scale: 6 ml/well. Concentration:
PvCTRP (162 mg in 200 ml) and PvWARP (58 mg in 200 ml).
(TIF)
Figure S6 VS1, a proof of concept molecular mimic of
apical midgut chondroitin sulfate glycosaminoglycan
binds to Plasmodium Circumsporozoite and Thrombos-
pondin Related Anonymous Protein Related Protein
(CTRP). (A) Homology model of Plasmodium falciparum CTRP
(Model 1) based on the crystal structure of human von Willebrand
Factor A1 (vWFA1) domain (PDB: 1AUQ). (B) Superposition of
the PfCTRP Homology (Model 1, gray) on the vWFA1 crystal
structure (1AUQ, blue). Structures/models for (B) and (C) are in
same orientation as Figure 5 (B–E). Note that the structure and
model are similar, with the exception of a few loops and the N-
and C-termini. (C) Superposition of Model 1 (gray) and Model 2
(Fig. 5 (D–E), based on Toxoplasma MIC2 structure, 2XGG) and
the same image rotated 180u in (D). The main difference between
Model 1 and Model 2 is shaded in red, which is an extra helix
modeled in Model 1 but is missing in Model 2.
(TIF)
Table S1 Data from direct feeding assays (DFAs)
summarized in Table 1 using the three compounds
tested in vivo with the Plasmodium berghei/mouse
system. Each tab includes data from two replicate experiments
for each compound and set of controls, both-pre- and post-
injection into P. berghei-infected mice. The tabs are labeled as
follows: S1A = VS1 10,000; S1B = VS1 3,000; S1C = VS1 1,000.
Data provided include the total number of mosquitoes dissected
and scored for oocysts after feeding on a given mouse (N), the
number of mosquitoes not infected (# Not Infected), the percent
prevalence (Prevalence), the median number of oocysts per midgut
(Median), the mean number of oocysts per midgut (Mean), and the
percent inhibition (% Inhibition) (for post-injection only, calculat-
ed as described in Table 1).
(XLSX)
Table S2 Male gametocyte exflagellation data from
Plasmodium berghei ANKA 2.34-infected mice pre- and
post-injection with either PBS (carrier-only control),
PVP (non-sulfated polymer control), or VS1-3000. Exflag-
ellation data from groups of 5 mice are presented in three columns
per treatment group. The first two columns show the average
number of exflagellation centers per 406 field from five fields
recorded both pre- and post-injection for individual mice. The
third column provides the P-value for a comparison at the group
level of the average number of exflagellation centers in pre- versus
post-injection mice. Note that a different set of mice was used for
each treatment (i.e., Mouse 1 is not the same between PBS, PVP,
and VS1 treatment groups).
(DOCX)
Text S1 This file contains the materials and methods
corresponding to the supplementary Figure S1 (Capil-
lary Electrophoresis Laser Induced Fluorescence analy-
sis of midgut BBMV Chondroitin sulfate GAGs), Figure
S2 (Determination of VS1 concentration in mouse
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